Join

Compare · NVO vs XCUR

NVO vs XCUR

Side-by-side comparison of Novo Nordisk A/S (NVO) and Exicure Inc. (XCUR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and XCUR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $183.15B, about 9610.3x XCUR ($19.1M).
  • Over the past year, NVO is down 44.6% and XCUR is down 70.7% - NVO leads by 26.1 points.
  • NVO has been more active in the news (8 items in the past 4 weeks vs 3 for XCUR).
  • NVO has more recent analyst coverage (25 ratings vs 2 for XCUR).
PerformanceNVO-47.29%XCUR-70.68%
2025-06-10+0.00%2026-06-09
MetricNVOXCUR
Company
Novo Nordisk A/S
Exicure Inc.
Price
$41.86+2.09%
$3.00+0.17%
Market cap
$183.15B
$19.1M
1M return
-9.23%
-13.53%
1Y return
-44.57%
-70.68%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
8
3
Recent ratings
25
2
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

XCUR

Exicure Inc.

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA–based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.

Latest NVO

Latest XCUR